Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 46 of 66 · 3128 articles
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
This study suggests adults with moderate-to-severe atopic dermatitis may have a higher-than-expected prevalence of IBD compared with general population estimates, and AD often precedes IBD—so dermatologists and patients...
This preclinical study suggests cigarette smoke alters gut microbes and metabolites in ways that can either protect or worsen colitis depending on the model; it identifies 4-HBA as a metabolite that reduced inflammation...
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
This study links bile-acid signaling through FXR in dendritic cells to regulation of Tph cells, a T-cell subset found in IBD. Understanding these immune pathways could point to new biological mechanisms relevant to...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
The study suggests a common food (edible bird's nest) may influence gut inflammation, barrier function, and microbiota in ways that could be relevant to IBD research and future dietary interventions.
Automating bowel wall thickness measurement could make intestinal ultrasound more consistent and reliable for monitoring inflammation in IBD, which matters to patients and clinicians tracking disease activity.
Patients with IBD who are frail appear to have a substantially higher risk of infections while on biologic therapies compared with fit patients. Recognizing frailty before and during treatment could improve risk...
This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...
The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
Based on the title and source metadata, this appears to be an observational study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from cureus.com.
People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
This registry will collect one-year, patient-reported outcomes on symptom control and clinical remission while people with IBD receive Zymfentra (infliximab-dyyb) in routine care — information that may help patients and...
Real-world data may help show how guselkumab performs in routine clinical practice for adults with moderate-to-severe UC who haven’t had prior biologics, information that could be useful to patients and clinicians...
New oral therapies in Phase 2/3 could expand treatment options for adults with moderate–severe Crohn's disease, including those who are naïve to advanced therapies or who failed prior biologics.
A new IL-23–targeting therapy (JNJ-78934804) is being tested against an approved IL-23 inhibitor (guselkumab) in a large Phase 3 trial for moderate–severe ulcerative colitis, which could affect future treatment options...
This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...
A new Phase 3 trial is testing icotrokinra, an oral investigational drug, for induction and maintenance of remission in moderate–severe ulcerative colitis. Trials like this could expand treatment options if the drug...
Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.
An AI-derived score that combines inflammation severity and extent may better predict relapse risk in ulcerative colitis than severity alone. That could help identify patients in endoscopic remission who still face...
The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future...
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
The study nominates specific compounds and molecular targets from a traditional herbal formulation that could be investigated as potential anti-inflammatory agents for ulcerative colitis, helping bridge chemical...
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...
Fatigue is a common, impactful symptom in pediatric and young-adult IBD but is poorly defined and measured, limiting the ability to design age-appropriate supports. This review highlights gaps that affect patients' daily...
Extraintestinal manifestations (EIMs) can significantly affect people with IBD and may require multidisciplinary care. Knowing how often EIMs are documented and which patients are more likely to have them helps...
The paper reports a material that preserved barrier proteins and reduced inflammatory signaling in cell and mouse models of ulcerative colitis; this could point to a low-cost adjunct approach for protecting the colonic...
PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...
Researchers found distinct microbial and host molecular features in the appendices of children with IBD, which could help explain local immune activation and guide future studies of disease mechanisms or biomarkers.
This research links a bacterial surface capsule to how well a gut microbe colonizes the intestine and to lower inflammatory responses in mouse models, which may help explain strain differences seen in Crohn’s disease and...
A market analysis listing late‑stage investigational therapies and growing use of IL‑23 and S1P pathway drugs signals potential new treatment options and changing prescribing patterns that may affect access, choice, and...
The work links fungal strain variation to differences in adhesion and immune recognition, which could help explain why a normally food-associated yeast is found in Crohn disease ulcers and point to microbial features...
If validated, transient modulation of epithelial E‑cadherin could become a new approach to promote mucosal healing — a key goal in IBD care. The findings point to epithelial repair biology rather than an approved patient...
The report shows a guideline-grounded AI tool for IBD professionals can be deployed internationally and attract repeated use, suggesting potential for AI to help synthesize guideline information.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
MR enterography is an important tool to measure transmural inflammation in ileal Crohn's disease, but many patients find the oral distension agents unpleasant. Demonstrating that non-distended MR enterography yields...
